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ABSTRACT 
Background:  Treatment of symptomatic congenital cytomegalovirus (CMV) disease with 6 
weeks of ganciclovir improves audiologic outcomes at 6 months, but benefits wane over time. 
Methods:  Randomized, placebo-controlled trial of 6 months or 6 weeks of valganciclovir in 
symptomatic congenital CMV disease. Primary endpoint was change in best ear hearing between 
baseline and 6 months. Secondary endpoints included change in hearing between baseline and 12 
and 24 months and neurodevelopmental outcomes, each adjusted for baseline central nervous 
system involvement. 
Results:  96 neonates were enrolled of whom 86 completed 6 months of therapy. Best-ear 
hearing outcomes at 6 months were similar for the groups [2 improved, 36 unchanged, 5 worse 
for 6-month group, versus 3, 37, and 3 respectively for 6-week group (p=0.41)].  Total ear 
hearing was more likely to be improved or remain normal at 12 months in the 6-month group 
(73.4%) versus the 6-week group (57.1%) (p=0.01). Benefit in total ear hearing was maintained 
at 24 months (77.1% vs. 63.8%, respectively; p=0.04]. The 6-month group had higher Bayley III 
Language Composite (84.6 vs. 72.5, p<0.01) and Receptive Communication Scale (7.3 vs. 5.2, 
p<0.01) neurodevelopmental scores at 24 months. Grade 3 or 4 neutropenia occurred in 19.3% 
during the first 6 weeks, and 21.3% (6-month group) vs. 26.5% (6-week group) during the next 
4.5 months of treatment (p=0.64). 
Conclusions:  Treating symptomatic congenital CMV disease with 6 months of valganciclovir, 
compared with 6 weeks, does not improve short-term hearing but appears to modestly improve 
longer-term hearing and developmental outcomes. (ClinicalTrials.gov number, NCT00466817) 
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Congenital cytomegalovirus (CMV) infection is the leading non-genetic cause of sensorineural 
hearing loss (SNHL)1-4 and the most frequent known viral cause of mental retardation,5 affecting 
0.6% to 0.7% of live births in industrialized countries.6-8  10% of congenitally infected neonates 
have symptomatic disease at delivery, of whom 35% have SNHL, up to two-thirds have 
neurologic deficits, and 4% die in the newborn period.7-11  Overall, congenital CMV is a rare 
infection but accounts for 21% of hearing loss at birth and 24% of hearing loss at four years of 
age.1, 12   
 
The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Antiviral Study 
Group (CASG) demonstrated that 6 weeks of intravenous ganciclovir for symptomatic 
congenital CMV disease involving the central nervous system (CNS) improved audiologic 
outcomes at 6 months of life, but there was suggestion that this benefit could wane over the first 
2 years of life.13  Treated infants had fewer developmental delays by Denver Developmental 
Evaluations.14  In a follow-up study, the CASG determined the dose of oral valganciclovir 
(ganciclovir’s prodrug) that achieves similar systemic ganciclovir exposure as intravenous 
ganciclovir.15  Six weeks of therapy with intravenous ganciclovir or oral valganciclovir is now an 
accepted treatment option for  symptomatic congenital CMV disease involving the CNS.16 
 
METHODS 
 
Study Design and Population 
Neonates with symptomatic congenital CMV disease, with or without CNS involvement, were 
eligible for enrollment.  Given the disease rarity, 40 study sites participated and each was 
anticipated to contribute only a few subjects.  All study subjects had CMV detected from urine or 
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throat swab specimens by culture, shell vial, or polymerase chain reaction (PCR).  Symptomatic 
disease was defined as ≥ one of the following:  thrombocytopenia, petechiae, hepatomegaly, 
splenomegaly, intrauterine growth restriction, hepatitis, or CNS involvement such as 
microcephaly, intracranial calcifications, abnormal cerebrospinal fluid (CSF) indices, 
chorioretinitis, SNHL, or detection of CMV DNA in CSF.  Subjects had a gestational age  32 
weeks, were ≤ 30 days of age, and weighed  1800 grams at initiation of therapy. 
 
Institutional review boards at each study center approved the protocol.  After written informed 
consent from the parent(s) or legal guardian(s), subjects received 6 weeks of valganciclovir (16 
mg/kg orally twice daily),15 followed by 1:1 randomization to continued valganciclovir or 
placebo for 4.5 months.  Study medication dose was adjusted monthly for growth.  Study 
medication was provided by Hoffmann-La Roche Inc. (Nutley, NJ), which had no input on study 
design, analyses, or manuscript development.  Study personnel and families were blinded to 
randomization assignment. 
 
The protocol pre-specified primary endpoint was change in hearing in best ear between baseline 
and the 6 month follow-up.13  Protocol pre-specified secondary endpoints included change in 
hearing in total ears between baseline and 6, 12, and 24 months; change in hearing in best ear 
between baseline and 12 and 24 months; neurologic impairment at 12 and 24 months; and 
adverse events leading to permanent discontinuation of therapy.  Tertiary endpoints included 
correlation of whole blood viral load with audiologic and neurodevelopmental outcomes, adverse 
events related to study medication, and characterization of ganciclovir blood concentrations. 
 
Audiologic Assessments 
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Brainstem evoked response (BSER) was performed at entry, and BSER or visual reinforcement 
audiometry (VRA) was performed at 6, 12, and 24 months.  Hearing thresholds were defined as:  
normal hearing 0-20 decibel (dB) thresholds, mild hearing loss 21-45 dB thresholds, moderate 
hearing loss 46-70 dB thresholds, and severe hearing loss  71 dB thresholds.3, 10, 13  An 
independent audiologist, masked to randomization assignment, reviewed all audiometry reports 
and classified evaluable ears by hearing thresholds, giving “total ear” classifications.  The study 
audiologist then assigned the “best ear” classification for the subject at that study visit; for 
example, if a subject had mild hearing loss in their left ear and severe hearing loss in their right 
ear, then the “best ear” classification was mild hearing loss.  Odd numbers of total ears by 
treatment category are reported because a patient may have only one evaluable ear [e.g., otitis 
media on one side (nonevaluable), normal ear on the other (evaluable)]. 
 
Neurodevelopmental Assessments 
The Bayley Scales of Infant and Toddler Development Third Edition was administered at 12 
and 24 months by a neuropsychologist at each site masked to randomization assignment.17 
 
Virologic Assessments 
Whole blood for CMV viral load18 was obtained at baseline, weekly for four weeks, every two 
weeks for eight weeks, and monthly for four months. 
 
Safety Assessments 
White blood cell count and differential, hemoglobin, platelet count, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), total bilirubin, and creatinine measurements were 
conducted serially.  Toxicity assessments were quantified with the NIAID Division of AIDS 
Toxicity Tables.19 
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Statistical Analyses 
The primary objective was to assess best ear hearing change from baseline to 6 months of age 
between 6-week versus 6-month therapy groups.  For the primary endpoint, the Wilcoxon/Mann-
Whitney test was used; linear models were used for secondary outcomes adjusting for covariates.  
For sample size purposes, 37 subjects per group produced a power of 85% to detect an effect size 
of 0.169 from the null value of 0.5.  With an expected 15% of subjects not eligible for 
randomization at 6 weeks and another 10% failing to complete the 6 month hearing evaluation, 
the original sample size was 94.  During the course of the study, the DSMB suggested that the 
sample size be increased to achieve the targeted 37 per group, due to inadequate baseline or 6 
month data.  The sample size then was increased to 104 in order to accommodate 10% 
unevaluable outcomes due to inadequate baseline or 6 month hearing data.  A 5% over-
enrollment was allowed for operational purposes. 
 
For the modified intention-to-treat (mITT) analysis population, participants must have taken at 
least one dose of blinded treatment.  The a priori study analysis plan dictated that efficacy 
outcomes be adjusted for CNS involvement.  For the primary endpoint, the Wilcoxon/Mann-
Whitney test was used.  For the secondary audiologic endpoints, hearing results were analyzed 
based upon two sets of binary outcomes:  1) improved hearing + normal hearing at baseline and 
follow-up, versus worsened hearing + same degree of hearing loss at baseline and follow-up; and 
2) worsened hearing, versus improved hearing + normal hearing at baseline and follow-up + 
same degree of hearing loss at baseline and follow-up (see Web-only Supplement for additional 
details).  Any hearing assessments completed after cochlear implantation were excluded, as were 
missing and unevaluable hearing assessments.  P-values<0.05 for hearing outcomes and p-
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values<0.0071 neurodevelopmental outcomes were considered significant.  No adjustments were 
made for multiplicity. For full details of the study conduct and analyses see the protocol and SAP 
at NEJM.org. 
 
RESULTS 
 
Subject Demographics and Characteristics 
From June 2008 through May 2011, 109 subjects from 31 study sites enrolled; 96 were 
randomized to blinded study medication (47 active drug, 49 placebo) after receiving 6 weeks of 
valganciclovir (Figure 1).  Nine (6 active, 3 placebo) of the 96 subjects stopped blinded drug 
before completing 6 months.  None discontinued treatment due to adverse events. 
 
Audiologic Outcomes 
Primary Study Endpoint 
For subjects receiving 6 months of treatment, change in best ear hearing between baseline and 6 
months was improved in 2, unchanged in 36, and worse in 5; for subjects receiving 6 weeks of 
treatment, 3 had improved hearing, 37 were unchanged, and 3 were worse (p=0.41). 
 
Secondary Study Endpoints 
Binary assessment of change in best ear hearing between baseline and 6 months was similar 
between the two treatment groups (p=0.24, adjusting for baseline CNS involvement; Table 2).  
Analysis of change in best ear hearing between baseline and 12 months and between baseline 
and 24 months approached statistical significance after adjusting for baseline CNS involvement 
(p=0.05 and p=0.07, respectively; Table 2). 
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Total ears from subjects receiving 6 months of valganciclovir were more likely to have improved 
hearing or maintain normal hearing between baseline and 12 months after adjusting for CNS 
involvement at baseline [OR (95% CI): 3.04 (1.26, 7.35); p=0.01] (Table 2).  Similar results 
were evident when prematurity and age at treatment initiation were added to the model (p=0.01).  
The relative risk for improved or protected total ear hearing between baseline and 12 months for 
the 53 subjects with baseline CNS involvement receiving 6 months of treatment and 6 weeks of 
treatment was 1.66 (95% CI: 0.92, 2.4), and the risk difference was 0.27 (95% CI: 0.09, 0.45).  
For the 28 subjects without baseline CNS involvement, the relative risk was 1.22 (95% CI: 0.99, 
1.45) and risk difference was 0.16 (95% CI: 0.03, 0.29). 
 
The benefit of longer-term therapy in the total ears analysis was maintained at 24 months, with 
improved outcomes after adjusting for CNS involvement at baseline [OR (95% CI): 2.61 (1.05, 
6.43); p=0.04] (Table 2).  Similar results were evident when prematurity and age at treatment 
initiation were added to the model (p=0.04).  The relative risk for improved or protected total ear 
hearing between baseline and 24 months for the 42 subjects with baseline CNS involvement 
receiving 6 months of treatment and 6 weeks of treatment was 1.46 (95% CI: 0.87, 2.05), and the 
risk difference was 0.23 (95% CI: 0.05, 0.41).  For the 26 subjects without baseline CNS 
involvement, the relative risk was 1.19 (95% CI: 0.98, 1.40) and risk difference was 0.14 (95% 
CI: 0.01, 0.27). 
 
Timing of initiation of valganciclovir within the first month of life (e.g., first three weeks of life 
versus weeks 3-4 of life) did not correlate with audiologic outcomes at 12 or 24 months (p>0.23). 
 
Neurodevelopmental Outcomes 
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Adjusting for CNS involvement at baseline, subjects randomized to 6 months of valganciclovir 
had higher Bayley III Language Composite (p=0.0046) and Receptive Communication Scale 
(p=0.0031) scores at 24 months compared with subjects randomized to 6 weeks of treatment 
(Table 3).  No significant interaction effects were found when outcome and baseline CNS 
involvement were incorporated in a single model, indicating similar treatment benefits for both 
groups (with and without CNS involvement).  These differences were maintained when age at 
treatment initiation and prematurity were added to the model (P-values of 0.0037 and 0.0027, 
respectively).  All other components of the Bayley assessments trended toward improved 
outcomes for subjects randomized to 6 months of therapy. 
 
Virologic Results 
Whole blood viral loads decreased in parallel during the first 6 weeks of open-label 
valganciclovir therapy, then diverged following randomization (Figure 2).  Adjusting for 
interaction effect between treatment and viral load area-under-the-curve (AUC), lower viral 
loads correlated with better hearing outcomes at 6, 12, and 24 months for subjects receiving 6 
months of treatment (p<0.01) but not for those receiving 6 weeks of treatment (p>0.68).  No 
correlation existed between viral load AUC and neurodevelopmental outcomes beyond that 
provided by treatment. 
 
Safety Assessments 
Twenty-one (19.3%) of the 109 subjects experienced Grade 3 or 4 neutropenia during the first 6 
weeks of open-label valganciclovir therapy.  Between week six and month six, ten (21.3%) of the 
47 active subjects experienced Grade 3 or 4 neutropenia compared with 13 (26.5%) of 49 
placebo subjects (p=0.64).  Three subjects had drug temporarily held for ANCs < 500 cells/mm3; 
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all treatment interruptions occurred within the first 6 weeks and resolved, following which 
treatment was continued. 
 
ALT and AST both increased slightly at Months 4 and 5 in the group receiving active drug, 
although differences were not statistically (p>0.59 for both ALT and AST) or clinically (mean ± 
SE values all < 90 U/L) significant.  No deaths occurred.  There were no significant differences 
in adverse events between the treatment groups. 
 
DISCUSSION 
 
Only one previous randomized controlled trial of antiviral treatment of symptomatic congenital 
CMV disease, also from the NIAID CASG, has been conducted.13  Other reports in the literature 
involve individual cases20-24 or small uncontrolled case series.25-27  The earlier randomized 
controlled trial demonstrated benefit of 6 weeks of parenteral ganciclovir therapy on best-ear 
hearing outcomes between baseline and 6 months, but there was suggestion that this benefit 
wanes over the first 2 years of life.13  Based on these data, change in best-ear hearing between 
baseline and 6 months was selected as the primary endpoint of this trial.  This positioned the 
current study to extend our knowledge of the impact of antiviral therapy on hearing, and allowed 
for sample size assessments in protocol development.  We also selected numerous clinically 
relevant secondary endpoints prior to initiation of the study to explore the impact of longer-term 
antiviral treatment on longer-term hearing improvement.  These included change in best ear and 
total ear hearing between baseline and 12 months and between baseline and 24 months in order 
to more completely ascertain the impact of antiviral treatment on shorter-term (first 6 months) 
and longer-term (to 2 years of age) time frames.  No previous study had prospectively assessed 
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the impact of antiviral treatment on neurodevelopmental outcome, so formal neurodevelopmental 
outcomes were incorporated as secondary endpoints in the study. 
 
We did not meet the primary study outcome of change in best ear hearing between baseline and 6 
months, with both study groups achieving similar results.  Total ear hearing between baseline 
and 6 months also was similar between the groups.  However, the secondary study outcomes of 
change in total ear hearing between baseline and 12 months and between baseline and 24 months 
were statistically significantly different between the groups, with subjects receiving the longer 
course of therapy having improved hearing outcomes compared with subjects receiving 6 weeks 
of treatment.  Data from our a priori secondary endpoints suggest that 6 months of antiviral 
treatment modestly improves longer-term hearing outcomes, but provides no additional benefit 
on shorter-term outcomes over that of 6 weeks of treatment.  The magnitude of the longer-term 
benefit can be viewed in different ways.  Using odds ratios, patients receiving longer therapy 
have 3-times the odds of improved hearing or protection of normal hearing at 12 months and 2.6-
times the odds at 24 months versus patients receiving shorter therapy.  Using relative risk, 
subjects with CNS involvement at baseline have a 65% and 46% increased likelihood of having 
better outcomes between baseline and 12 and 24 months, respectively, while for subjects without 
CNS involvement these values are 22% and 19%, respectively.  Risk differences between the 
groups range from 0.14 to 0.27, depending on baseline CNS involvement and follow-up interval.  
We encourage caution that spurious findings may have arisen from the multiple statistical tests 
conducted for the secondary hearing outcomes considered in this report. 
 
Employing the Bayley III17and utilizing the Bonferroni adjustment for multiple testing, the 
communicative outcomes of language composite score and receptive communication scale were 
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improved with longer treatment, with low average results among subjects treated for 6 months 
but borderline results among subjects treated for 6 weeks following adjustment for factors that 
could impact development.  All other components of the Bayley Scales also were higher in the 6 
month treatment group (Table 3), although statistically significant.  No significant interaction 
effects were found, indicating similar neurologic treatment benefits for groups with and without 
CNS involvement. 
 
Subjects receiving oral valganciclovir had lower rates of Grade 3 or Grade 4 neutropenia during 
the first 6 weeks of treatment (19.3%) than treated subjects in previous CASG studies of 6 weeks 
of intravenous ganciclovir (63.0%)13 or of two weeks of intravenous ganciclovir and four weeks 
of oral valganciclovir (37.5%),15 perhaps due to the Cmax of intravenous versus oral drug 
delivery.  From week six to month seven in the current trial, subjects randomized to continuation 
of valganciclovir had similar incidence of Grade 3-4 neutropenia compared with subjects 
randomized to placebo (21.3% versus 26.5%; p=0.64).  Thus, drug-induced neutropenia is of 
primary concern during the first 6 weeks of treatment, and the risk appears to be lower when 
treatment is solely with oral valganciclovir.13 Ganciclovir is gonadal toxic and carcinogenic in 
animal models,28 and while these toxicities have not been seen in humans they should be 
conveyed to families of babies for whom valganciclovir therapy is being considered. 
 
These controlled data suggest moderately favorable impact of 6 months of oral valganciclovir on 
longer-term audiologic and neurodevelopmental outcomes adjusting for baseline CNS 
involvement in infants with symptomatic congenital CMV disease, without excess risk of 
neutropenia or the risk associated with maintaining intravenous access for prolonged periods of 
time. These data do not apply to infants with asymptomatic congenital CMV infection, since 
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there are no controlled studies documenting benefit in this population and the possibility of harm 
exists. Since CMV-associated sensorineural hearing loss fluctuates over time in more than one-
third of patients as part of the natural history of disease, prospective, controlled trial designs are 
critical to assess treatment benefit in congenital CMV infections. 
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Figure Legends 
Figure 1.  Randomization and Follow-up of Study Participants 
Figure 2.  Whole Blood CMV DNA Viral Load for Subjects receiving 6 Months (green) and 6 
Weeks (red) of Therapy; viral load <100 was replaced by viral load =10 in the figure 
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Table 1. Baseline Demographics* 
 
6 Months of 
Therapy (N=47) 
6 Weeks of 
Therapy 
(N=49) 
P-value 
Gestational Age by Category [N (%)] 
Preterm (32 to ≤ 37 weeks gestational age) 24 ( 51.1 ) 22 ( 44.9 ) 0.68 
Term (> 37 weeks gestational age) 23 ( 48.9 ) 27 ( 55.1 )  
Age at enrollment (by grouping) [N (%)] 
< 7 days   6 ( 12.8 )   7 ( 14.3 ) 0.08 
7-14 days 19 ( 40.4 ) 12 ( 24.5 )  
15-21 days 10 ( 21.3 )   6 ( 12.2 )  
21- < 30 days 12 ( 25.5 ) 24 ( 49.0 )  
Extent of CMV Disease† [N (%)] 
Thrombocytopenia 38 ( 80.8 ) 34 ( 69.4 ) 0.24 
Petechiae 22 ( 46.8 ) 20 ( 40.8 ) 0.68 
Hepatomegaly 26 ( 55.3 ) 21 ( 42.9 ) 0.31 
Splenomegaly 23 ( 48.9 ) 22 ( 44.9 ) 0.84 
Intrauterine growth restriction 17 ( 36.2 ) 22 ( 44.9 ) 0.41 
Hepatitis (elevated transaminases or bilirubin) 21 ( 44.7 ) 25 ( 51.0 ) 0.55 
Central nervous system involvement 34 ( 72.3 ) 29 ( 59.2 ) 0.20 
Microcephaly 14 (29.8) 17 (34.7) 0.19 
Chorioretinitis 2 (4.3) 1 (2.0) 1.00 
Neuroimaging Results (MRI, CT, HUS) [N (%)] 
Normal 9 (20.0) 12 (25.5) 0.62 
Abnormal 36 (80.0) 35 (74.5)  
Baseline BSER (best ear) for subjects evaluable at 6 months [N (%)] 
 N=43 N=43 0.17 
Normal 32 (74.4) 25 (58.1)  
Mild 5 (11.6) 8 (18.6)  
Moderate 3 (7.0) 2 (4.7)  
Severe 3 (7.0) 8 (18.6)  
* See Table S1 in Web-only Supplement for full tabulation of Baseline Demographics 
† Subjects could have multiple manifestations of CMV disease 
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Table 2.  Improvement and protection in hearing among best ear and total ears between baseline and follow-up 
 
 6 Month Follow-up 12 Month Follow-up 24 Month Follow-up 
 Best Ear Analysis  
 
(Primary Endpoint)* 
Total Ears Analysis 
(Secondary 
Endpoint)* 
Best Ear Analysis 
 
(Secondary 
Endpoint)* 
Total Ears Analysis 
(Secondary 
Endpoint)* 
Best Ear Analysis 
 
(Secondary 
Endpoint)* 
Total Ears Analysis 
(Secondary 
Endpoint)* 
Duration of Valganciclovir Therapy 6 months 
(n=43) 
6 weeks 
(n=43) 
6 months 
(n=82) 
6 weeks 
(n=84) 
6 months 
(n=41) 
6 weeks 
(n=40) 
6 months 
(n=79) 
6 weeks 
(n=77) 
6 months 
(n=37) 
6 weeks 
(n=31) 
6 months 
(n=70) 
6 weeks 
(n=58) 
Improved Hearing 2 (4.7%) 3 (7.0%) 6 (7.3%) 7 (8.3%) 2 (4.9%) 2 (5.0%) 6 (7.6%) 4 (5.1%) 2 (5.4%) 2 (6.5%) 6 (8.6%) 2 (3.5%) 
Normal Hearing at Baseline and 
Follow-up 
28 
(65.1%) 
23 
(53.5%) 
46 
(56.1%) 
39 
(46.4%) 
30 
(73.2%) 
23 
(57.5%) 
52 
(65.8%) 
40 
(50.6%) 
30 
(81.1%) 
20 
(64.5%) 
48 
(68.6%) 
35 
(60.3%) 
Same Degree of Hearing Loss at 
Baseline and Follow-Up 
8 (18.6%) 
14 
(32.6%) 
19 
(23.2%) 
29 
(34.5%) 
6 (14.6%) 
10 
(25.0%) 
15 
(19.0%) 
23 
(29.9%) 
2 (5.4%) 7 (22.6%) 8 (11.4%) 
16 
(27.6%) 
Worsened Hearing 
5 (11.6%) 3 (7.0%) 
11 
(13.4%) 
9 (10.7%) 3 (7.3%) 5 (12.5%) 6 (7.6%) 
10 
(13.0%) 
3 (8.1%) 2 (6.5%) 8 (11.3%) 5 (8.6%) 
Improved/Protected Hearing versus 
Other,† Unadjusted Analysis 
p=0.50 p=0.34 p=0.15 p=0.08 p=0.14 p=0.13 
 
OR (95% CI): 
1.51 (0.62, 3.68) 
OR (95% CI): 
1.45 (0.67, 3.15) 
OR (95% CI): 
2.13 (0.80, 5.67) 
OR (95% CI): 
2.18 (0.92, 5.18) 
OR (95% CI): 
2.62 (0.77, 8.87) 
OR (95% CI): 
1.99 (0.82, 4.83) 
 
RR (95% CI): 
1.15 (0.84, 1.58) 
RR (95% CI): 
1.17 (0.85, 1.61) 
RR (95% CI): 
1.25 (0.93, 1.67) 
RR (95% CI): 
1.32 (0.97, 1.79) 
RR (95% CI): 
1.22 (0.94, 1.58) 
RR (95% CI): 
1.23 (0.93, 1.62) 
 
RD (95%CI): 
0.09 (-0.11, 0.29) 
RD (95% CI): 
0.09 (-0.10, 0.28) 
RD (95% CI): 
0.16 (-0.04, 0.35) 
RD (95% CI): 
0.18 (-0.01, 0.37) 
RD (95% CI): 
0.16 (-0.04, 0.35) 
RD (95% CI): 
0.14 (-0.04, 0.33) 
Improved/Protected Hearing versus 
Other, † Adjusted for CNS 
involvement at baseline‡ 
p=0.24 p=0.20 p=0.05 p=0.01 p=0.07 p=0.04 
OR (95% CI): 
1.75 (0.69, 4.43) 
OR (95% CI): 
1.69 (0.76, 3.73) 
OR (95% CI): 
2.81 (0.99, 7.99) 
OR (95% CI): 
3.04 (1.26, 7.35) 
OR (95% CI): 
3.28 (0.91, 11.9) 
OR (95% CI): 
2.61 (1.05, 6.43) 
 
OR: Odds Ratio; RR: Risk Ratio; RD: Risk Difference; CI: Confidence Interval 
*  All of the analyses for the primary and secondary endpoints were pre-specified in the protocol 
†  Improved hearing or normal at baseline and follow-up, versus worsened hearing or same degree of hearing loss at baseline and follow-up 
‡  Adjustment for CNS involvement at baseline was determined a priori 
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Table 3.  Treatment Effects on Neurological Outcomes by Randomization Group* 
Bayley III 
Component 
Month 12 Follow-up Month 24 Follow-up 
6 Months of 
Therapy 
6 Weeks of 
Therapy P-Value 
6 Months of 
Therapy 
6 Weeks of 
Therapy P-Value 
Cognitive Composite  
N 43 45 
0.0128 
42 41 
0.0236 Mean ± SE 89.6 ± 3.0 79.5 ± 2.8 84.4 ± 2.6 76.0 ± 2.6 
(Min-Max)† 55-115 9.5-120 55-135 55-110 
Language Composite  
N 41 43 
0.0090 
41 41 
0.0037 Mean ± SE 87.6 ± 3.0 76.8 ± 2.9 84.6 ± 2.9 72.5 ± 2.9 
(Min-Max)† 47-118 11-112 47-121 47-103 
Receptive  Communication Scale   
N 41 43 
0.0544 
41 41 
0.0027 Mean ± SE 7.5 ± 0.5 6.1 ± 0.5 7.3 ± 0.5 5.2 ± 0.5 
(Min-Max)† 1-14 1-12 1-14 1-10 
Expressive Communication Scale 
N 41 44 
0.0224 
41 41 
0.0158 Mean ± SE 8.0 ± 0.5 6.5 ± 0.5 7.3 ± 0.5 5.5 ± 0.5 
(Min-Max)† 1-13 1-13 1-13 1-11 
Motor Composite  
N 42 44 
0.0289 
41 40 
0.0130 Mean ± SE 82.6 ± 3.2 73.2 ± 3.0 85.5 ± 3.3 74.1 ± 3.2 
(Min-Max)† 46-112 11-112 46-121 46-121 
Fine Motor Scale 
N 41 44 
0.1132 
42 40 
0.0566 Mean ± SE 7.3 ± 0.6 6.0 ± 0.6 8.0 ± 0.6 6.4 ± 0.6 
(Min-Max)† 1-11 0.1-13 1-15 1-19 
Gross Motor Scale 
N 42 44 
0.0672 
42 40 
0.0198 Mean ± SE 6.7 ± 0.5 5.4 ± 0.5 7.0 ± 0.5 5.3 ± 0.5 
(Min-Max)† 1-14 0.1-15 1-13 1-12 
 
* Adjusted for CNS involvement at baseline, prematurity, and age at treatment initiation. P-values < 0.0071 (= 
0.05/7) considered statistically significant, using Bonferroni adjustment for multiple testing. 
† Minimum and maximum values of the raw data 
